2Strands Biosciences successfully completed the 13-week NUS Medicine/22Health Accelerator Programme, culminating in a Demo Day on 14 December 2024.
Throughout the programme, 2Strands connected with experienced founders, healthcare leaders and industry experts who provided strategic guidance and valuable market insights. The programme also offered personalised mentorship and support in navigating regulatory pathways, forming strategic partnerships and securing key industry introductions.
This experience has helped to strengthen 2Strands’ strategy in advancing its ultrasensitive ctDNA detection technology for minimal residual disease (MRD) monitoring.
Watch 2Strands pitch on the Demo Day here: https://www.youtube.com/watch?v=0RPlObch7wY